-
TAK-242: Translating TLR4 Biology into Strategy
2026-09-30
TAK-242 (Resatorvid) offers translational researchers a selective way to interrogate TLR4-driven inflammation at the receptor-proximal level. This thought-leadership guide connects its mechanism and preclinical evidence in autoimmune peripheral neuropathy with practical study design, model selection, and the limits of translating pathway inhibition across inflammatory diseases.
-
Masitinib (AB1010) Workflow and QC Guide
2026-09-30
Masitinib (AB1010), SKU A2942, is a DMSO-compatible research inhibitor for focused KIT, PDGFRα, and PDGFRβ studies, including mast-cell and selected KIT-mutant cell workflows. It should not be used as a substitute for clinical guidance, broad-spectrum kinase profiling, or protocols that require an aqueous or ethanol vehicle.
-
Lipo3K Transfection Reagent for ccRCC Studies
2026-09-29
Build low-toxicity DNA, siRNA, and co-transfection workflows for dissecting OTUD3–SLC7A11 signaling and sunitinib resistance in clear cell renal cell carcinoma. Lipo3K combines serum-compatible delivery with an optional plasmid enhancer, making it useful for both difficult cell models and mechanism-focused validation assays.
-
Streptozotocin: Designing Diabetes–Neuropathy Models
2026-09-29
Streptozotocin and STZ are more than diabetes-induction tools: they enable controlled separation of β-cell injury, hyperglycemia, and neuroimmune complications. This guide translates recent TBK1–microglia findings into practical model and assay decisions.
-
Gamithromycin BA1074: Assay Design & Interpretation
2026-09-28
A scenario-led guide to using Gamithromycin (SKU BA1074) in pathogen-focused research, with practical guidance on assay selection, serum effects, handling, and data interpretation. It distinguishes antimicrobial endpoints from mammalian-cell viability readouts and anchors numerical claims to the cited study and product information.
-
Human iPSC Sensory Neurons Model HSV-1 Latency
2026-09-27
Oh and colleagues developed a scalable method for differentiating human iPSCs into sensory neurons and showed that HSV-1 can establish a latent state in these cells and respond to established reactivation stimuli. The model combines neuronal-function checks with viral gene-expression and chromatin readouts, providing a human-cell platform for studying latency while leaving questions about in vivo relevance and neuronal diversity open.
-
hiPSC Intestinal Organoids for Pharmacokinetic Studies
2026-09-26
Saito and colleagues report a direct three-dimensional culture approach for deriving expandable intestinal organoids from human induced pluripotent stem cells, then differentiating them into intestinal epithelial cells in monolayer culture. The model combines long-term propagation and cryopreservation with CYP enzyme and transporter activities, offering a human-cell platform for pharmacokinetic research while leaving assay-specific performance and broader transferability to be established.
-
Sisomicin in Bacterial Infection Research
2026-09-26
Use Sisomicin to build concentration-response, susceptibility, and time-kill experiments across bacterial models, while keeping strain-specific resistance and assay context in view. A workflow inspired by paired intra- and extracellular antibiotic testing helps distinguish broth potency from activity in more complex infection models—without assuming results transfer between drugs.
-
Testosterone Bounce Predicts Outcomes With Degarelix
2026-09-25
In a retrospective cohort of 120 prostate cancer patients treated with degarelix, a defined testosterone bounce was associated with better overall and cancer-specific survival, but not progression-free survival. The study suggests that serial testosterone measurements may add prognostic information, while its observational design means the finding requires validation before clinical use.
-
JNK-IN-7: Testing JNK Causality in Apoptosis
2026-09-25
JNK-IN-7 is a selective JNK inhibitor for testing whether JNK activity contributes to apoptosis rather than simply accompanying it. This article connects its pharmacology to Candida krusei–induced epithelial cell death and offers a careful framework for interpreting pathway perturbation experiments.
-
CD4 T-Cell Costimulation Drives Antitumor Immunity
2026-09-24
Cho and colleagues tested whether RNA-transfected CD4 T cells expressing CD80, 4-1BBL, or both could act as cellular vaccines. In mouse tumor models, the dual-ligand cells improved CD8 T-cell responses and were associated with tumor control and memory, supporting further study while leaving important protocol and translational questions open.
-
Cefiderocol Against Resistant European Non-Fermenters
2026-09-24
A multicountry in vitro study compared cefiderocol with β-lactam/β-lactamase inhibitor combinations against 1,451 European Pseudomonas aeruginosa and Acinetobacter spp. isolates. Cefiderocol susceptibility was high, including among many meropenem-resistant isolates, but results for resistant Acinetobacter subgroups and the study’s in vitro design underscore the need for isolate-specific testing and cautious clinical interpretation.
-
Aztreonam and the Next Wave of Resistance Research
2026-09-23
Aztreonam is more than a targeted antibacterial reagent: it is a mechanistically defined tool for connecting Gram-negative resistance biology with host-cell and hepatic pharmacology. This article translates recent carbapenem-resistant Enterobacter cloacae findings into practical assay strategy while defining the limits of current evidence.
-
TG003 Cdc2-like Kinase Inhibitor Guide
2026-09-23
TG003 is an ATP-competitive Cdc2-like kinase inhibitor that preferentially inhibits Clk1 and Clk4 and modulates serine/arginine-rich protein phosphorylation. Its research value spans alternative splicing modulation, splice site selection research, and preclinical exon-skipping therapy workflows, while its activity against CK1 and limited Clk2 selectivity require appropriate controls.
-
Antiseptics for Burns: What the Evidence Shows
2026-09-22
The Cochrane review of antiseptics for burns synthesizes randomized and quasi-randomized evidence on wound healing, infection, and treatment-related harms. Its central implication is that antimicrobial activity alone does not establish better clinical healing, and that heterogeneous, low-certainty evidence limits confident selection among antiseptic strategies.